Bluejay Therapeutics
Mary Cromwell serves as Senior Vice President and Head of Technical Operations at Bluejay Therapeutics since February 2025. Prior to this role, Mary worked at Allakos Inc from July 2023 to February 2025 as Chief Technical Officer, after holding positions as Senior Vice President, Head of Technical Operations and Senior Vice President, Process Development and Manufacturing at the same company. Mary’s extensive career began at Genentech, where roles included Vice President, Head of Quality Drug Substance, and Vice President and Head of Global Biologics MSAT and Global Packaging Development, among others, spanning from July 1989 to February 2022. Mary holds a Doctor of Philosophy (Ph.D.) in Pharmaceutical Sciences from the University of Colorado Denver, a Master of Science (MS) in Chemistry from the University of California, Berkeley, and a Bachelor of Science (BS) in Chemistry from West Virginia University.
This person is not in any teams
This person is not in any offices
Bluejay Therapeutics
Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases. The company’s first target indication is chronic Hepatitis B, which remains a worldwide prevalent disease with urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for high rate offunctional cure: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class HBsAg oral small molecule inhibitors. The company believes that by reducing hepatitis B surface antigen and restoring adaptive immunity a functional cure could be achieved for patients.